Global Antifibrinolytic Drugs Market - 2022-2029

Global Antifibrinolytic Drugs Market - 2022-2029

Market Overview

The global antifibrinolytic drugs market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Antifibrinolytic medications are used to prevent fibrinolysis or the lysis of blood clots or thrombosis. Fibrinolysis removes excess fibrin by stimulating plasminogen to promote fibrin clot formation and wound healing. Tissue plasminogen activators and other plasminogen activators are also used as first-line mediators in lysis therapy. Fibrinolysis inhibitors act when plasminogen is converted to plasmin, either by blocking plasmin's lysine binding sites or by actively inhibiting plasmin via serine protease inhibition. Antifibrinolytic drugs are commonly used to inhibit fibrinolysis and are thus referred to as lysine analogs. The medications are used to treat massive bleeding and other coagulation disorders.

Market Dynamics

The global antifibrinolytic drugs market growth is driven due to an increase in severe road accidents, complicated medical surgeries and procedures, angioedema prevalence, and an increase in the high-risk geriatric population worldwide.

An increase in number of medical surgeries performed each year will drive the market growth

The major factors driving the growth of the antifibrinolytic drugs market are a significant increase in road accidents, accidental trauma, an increase in medical surgeries, an increase in the incidence of angioedema, and an increase in the high-risk geriatric population around the world. According to the National Trauma Institute in the United States, trauma is the leading cause of death in people aged 1 to 65 years. Furthermore, according to the World Health Organization, approximately 1.35 million people die each year due to traffic accidents.

Furthermore, these medications are widely used to prevent heavy menstrual bleeding in women, a condition known as menorrhagia. These drugs are also used following surgeries such as cardiovascular and neurosurgeries to prevent massive blood loss from the patient's body. Cardiovascular diseases are the leading cause of death worldwide. In 2019, 17.9 million people died from cardiovascular diseases, accounting for 32% of global deaths. Eighty-five heart attacks or a stroke caused 85 percent of these deaths. More than three-quarters of cardiovascular diseases deaths occur in low- and middle-income countries.(Source:World Health Organization) Bleeding disorders interfere with blood clotting and can cause excessive bleeding inside and outside the body. Bleeding disorders are almost always inherited, and symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from minor cuts. Von Willebrand disease and Hemophilia A and B are the most common bleeding disorders. In 2019, approximately 195,263 people worldwide were diagnosed with hemophilia, and 80,302 were diagnosed with von Willebrand disease. The significant increase in the prevalence of bleeding disorders drives the growth of the antifibrinolytic drugs market.

Side effects caused by antifibrinolytic drugs is likely to hamper the market growth

Antifibrinolytic drugs use comes with many negative side effects, including nausea, diarrhea, stomach pain or discomfort, vomiting, chills, fever, severe headache, back or joint pain are stifling the worldwide antifibrinolytic drugs market's expansion. Any drug's use is restricted because the government establishes guidelines to monitor how and where the medications are utilized. This is expected to influence the market for androgens and anabolic steroids negatively. Furthermore, these medicines have negative effects that may cause them to be used less frequently. To overcome these limitations, the market must continue to develop and upgrade.

COVID-19 Impact Analysis

During the COVID-19 pandemic, the antifibrinolytic drugs market has shrinked significantly. The pandemic has made it tougher to bring new medications to market in the hopes of earning market share or reaching sales projections. Aside from new diagnoses and regimen switching, marketing channels aren't as strong as before the epidemic. The few open channels continue to be dominated by COVID-19 programming. COVID-19 has slowed down clinical trials across the board, notably those in the early stages of development. As traditional study sites closed, researchers were often unable to collect data remotely, and many patients became less willing to participate. Some therapeutic fields were particularly heavily damaged. While some development time can be made up, there are concerns about resource allocation and digital technology expenditures to keep trials running now and in the future.

Segment Analysis

The gynecology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The gynecology segment accounted for most of the antifibrinolytic drugs market share in 2018 and is expected to exhibit a significant growth rate soon, owing to increased adoption of these drugs to prevent menorrhagia or heavy menstrual flow. Furthermore, these drugs are designed to reduce bleeding by inhibiting the uterine lining's endometrial clot-dissolving enzymes. Tranexamic acid (TXA) is the most commonly used drug to treat menorrhagia.

In 2015, the maternal death rate in underdeveloped countries was 239 per 100,000 live births, compared to 12 per 100,000 in industrialized countries. Thus, developing nations account for 99 percent of all maternal mortality, with more than half of these deaths occurring in Sub-Saharan Africa and nearly a third in South Asia. Maternal deaths account for only 1% of all deaths in the affluent world. There are significant differences between nations and within countries; maternal deaths are higher in low-income and rural areas than in high-income and metropolitan areas.

Every day, over 830 women die around the world as a result of pregnancy or childbirth difficulties. The three most preventable causes of maternal death are hemorrhage, sepsis, and hypertensive disorders, which account for 52 percent of all maternal deaths. According to WHO figures, PPH is responsible for 25% of maternal fatalities. Postpartum bleeding is the most lethal of maternal killers; even a healthy woman can die within two hours if left untreated.

Postpartum hemorrhage occurs in 2% to 4% of women after vaginal delivery and 6% of women following cesarean delivery, with uterine atony being the reason in around half of the cases. PPH affects around 14 million women worldwide each year.

Geographical Analysis

North America region holds the largest market share of the global antifibrinolytic drugs Market

North America is anticipated to dominate the antifibrinolytic drugs market globally. The factors attributed to the region's high growth are the increasing awareness about antifibrinolytic drugs, along with various chronic diseases, and the government and private players have made significant investments in R&D and healthcare spending. According to an article published by the Center for Disease Control and Prevention updated in April 2021, six in ten adults in the United States have at least one chronic disease. Four in ten adults have two or more chronic diseases like cardiovascular, neurological diseases. Thus, the country's high prevalence of chronic diseases increases the demand for surgeries, thus driving the antifibrinolytic drugs market.

Furthermore, organic and inorganic strategies such as mergers and acquisitions and partnerships among key market players will strengthen their product portfolios in the studied market, driving the market. In addition, several product launches in the market will lead to profitable market growth. For instance, in January 2016, The United States Food and Drug Administration (USFDA) has approved Aurobindo Pharma Ltd to manufacture and market Tranexamic Acid Injection (100 mg/mL) 1000 mg/10 mL single-dose vial. Furthermore, advancements in various antifibrinolytic drugs from established key players, in the United States, are likely to drive the market growth in North America.

Competitive Landscape

The antifibrinolytic drugs market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amring Pharmaceuticals, Aurobindo Pharmaceuticals, Akorn, Pfizer, Kraeber & Co GMBH, CSL Behring among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antifibrinolytic drugs market globally. For instance, on December 1, 2020, Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical company, announced that it had agreed with Ferring International Center S.A. to acquire the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). Since March 14, 2016, Amring has marketed the authorized generic version of LYSTEDA in the United States.

Pfizer Inc

Overview:

Pfizer Inc. (Pfizer) is a global biopharmaceutical corporation founded on research. Biopharmaceutical products are discovered, developed, manufactured, marketed, sold, and distributed. Medicines and vaccines are part of the company's global portfolio. The company develops health, prevention, treatments, and cures across markets. To support and offer access to healthcare, it collaborates with healthcare providers, governments, and local communities. Its medications and vaccines benefit healthcare providers and patients by treating diseases and improving health and wellness. Wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies customers for their prescription pharmaceutical items. It sells vaccines to the federal government, the Centers for Disease Control and Prevention (CDC), wholesalers, single provider offices, retail pharmacies, and integrated delivery networks in the United States.

Product Portfolio:

Aminocaproic acid: The FDA has approved aminocaproic acid (Amicar) to treat acute bleeding caused by increased fibrinolytic activity. The FDA has also designated it an orphan medication to prevent recurrent bleeding in patients with traumatic hyphema.

Why Purchase the Report?

Visualize the composition of the global antifibrinolytic drugs market segmentation by indication, drug types, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global antifibrinolytic drugs market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global antifibrinolytic drugs market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global antifibrinolytic drugs market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Antifibrinolytic Drugs Market– By Indication

Gynecology

Menorrhagia

Pregnancy

Parturition

Gynecological Surgery

Gastrointestinal Bleeding

Hemorrhage

Bleeding Disorders

Hereditary Angioedema

Fibrinolytic Response Testing

Surgeries

Cardiac

Liver

Neurosurgery

Dental Surgery

Global Antifibrinolytic Drugs Market- By Drug Type

Amicar

Aminocaproic acid

Aprotinin

Cyklokapron

Fibrogen

Lysteda

RiaSTAP

Tranexamic Acid Oral

Trasylol

Global Antifibrinolytic Drugs Market– By End User

Hospitals

Ambulatory Surgical Centers

Clinics

Health Care Speciality Process

Others

Global Antifibrinolytic Drugs Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America